^
BIOMARKER:
MGMT promoter methylation
i
Other names: MGMT, Methylated-DNA--protein-cysteine methyltransferase, 6-O-methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase
Entrez ID:
Related biomarkers:
›
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
MGMT promoter methylation
|
Ewing Sarcoma
|
MGMT promoter methylation
|
Ewing Sarcoma
|
temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria
|
temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
cilengitide Sensitive: C3 – Early Trials
|
cilengitide Sensitive: C3 – Early Trials
|
MGMT promoter methylation
|
Glioma
|
MGMT promoter methylation
|
Glioma
|
temozolomide + carmustine Sensitive: C3 – Early Trials
|
temozolomide + carmustine Sensitive: C3 – Early Trials
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
ruxolitinib Sensitive: C3 – Early Trials
|
ruxolitinib Sensitive: C3 – Early Trials
|
MGMT promoter methylation
|
Glioma
|
MGMT promoter methylation
|
Glioma
|
ruxolitinib Sensitive: C3 – Early Trials
|
ruxolitinib Sensitive: C3 – Early Trials
|
